Updates in HIV PrEP Therapy Options

Recent updates to U.S. guidelines for HIV post‑exposure prophylaxis (PEP) provide modernized recommendations for both non‑occupational and occupational exposures — reflecting advances in antiretroviral therapy and evolving evidence. This course summarizes key changes, including preferred regimens, testing/follow‑up modifications, and special‑population considerations, and explores how these updates influence clinical practice. You will gain the practical knowledge needed to inform prompt PEP decision‑making, patient counseling, and care coordination.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTKenric Ware, Pharm D Clinical Associate Professor of Pharmacy PracticeMercer UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify current guideline recommendations for initiating HIV PEP after occupational and non-occupational exposure.2. Describe key considerations for selecting and managing HIV PEP regimens.Rachel Maynard and Kenric Ware have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-052-H01-PInitial release date: 2/16/2026Expiration date: 2/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent developments in HIV prevention — including the FDA approval of a 6‑month injectable option and updated clinical guidance — are changing the landscape of Pre-Exposure Prophylaxis (PrEP) therapy. This course reviews the latest developments, compares prevention strategies, and examines how these changes affect PrEP delivery, counseling, and monitoring. You will gain timely insights to better counsel patients, support adherence, and contribute to prevention strategies in your practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTDavid Hachey, PharmD, AAHIVP Professor Idaho State University GET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe key new HIV PrEP therapy options recently approved or recommended, including their dosing schedules and clinical indications.2. Identify pharmacist responsibilities when counseling patients about PrEP, including initiation, adherence, monitoring, and risk-benefit discussions. Rachel Maynard and David Hachey have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-049-H01-PInitial release date: 2/9/2026Expiration date: 2/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTReemal Zaheer, PharmD, CSPPharmacistJohns Hopkins MedicineGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of biosimilars in the treatment of inflammatory conditions.2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies.Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 HrUAN: 0107-0000-26-045-H01-PInitial release date: 2/2/2026Expiration date: 2/2/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTErin Raney, PharmDProfessorMidwestern University College of PharmacyGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy.2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 HrUAN: 0107-0000-26-044-H01-PInitial release date: 1/26/2026Expiration date: 1/26/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagramFollow CEimpact on Social Media:LinkedInInstagram

Ranitidine — once withdrawn from the market over safety concerns — was recently re‑approved by the FDA in a reformulated version, raising important questions for pharmacists and patients alike. This course outlines the FDA’s recent approval, reviews the reformulated product's changes (including manufacturing and labeling), and examines practical considerations for dispensing, counseling, and patient safety. You will gain clarity on when ranitidine may be appropriate for use (again) and how to guide patients confidently in its safe use.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTK. Ashley Garling-Nanez, PharmDAssistant Director of ProgramUT Center of Health CommunicationsGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize the major safety and regulatory issues that prompted ranitidine's withdrawal, and the changes made in the reformulated product approved in 2025.2. Describe pharmacist‑relevant considerations for dispensing, patient counseling, and transition from alternative acid‑reducing therapies.Rachel Maynard and K. Ashley Garling-Nanez have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-043-H01-PInitial release date: 1/19/2026Expiration date: 1/19/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristina O'Connor, PharmD, BCPS, BCIDPClinical Pharmacy ManagerMayo ClinicGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence.2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education.Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-038-H01-PInitial release date: 1/12/2026Expiration date: 1/12/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Corticosteroids in the treatment of community-acquired pneumonia (CAP) remain a topic of clinical curiosity and mixed opinions. In this unique episode, two expert guests share opposing perspectives—one advocating for corticosteroid use in CAP and the other urging caution—offering pharmacists a balanced view of the current evidence and practice considerations. Tune in to explore both sides of the debate and walk away with insights to inform your role in collaborative patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSSam Markle, PharmDCritical Care PharmacistSanford HealthTristan Houle, PharmDPGY2 Critical Care Pharmacy ResidentSanford HealthPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current evidence supporting and challenging the use of corticosteroids in the treatment of community-acquired pneumonia (CAP).2. Identify key considerations for pharmacists when evaluating corticosteroid use as adjunctive therapy in CAP.Rachel Maynard, Sam Markle, and Tristan Houle have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-032-H01-PInitial release date: 1/5/2026Expiration date: 1/5/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

As cannabis becomes more widely available and socially accepted, so does the misconception that it's safe to use during pregnancy and lactation. This course reviews updated guidance from the American College of Obstetricians and Gynecologists (ACOG), highlighting the evidence behind the risks and outlining how pharmacists can address misinformation and counsel patients effectively. You will learn how to support safe, informed decision-making that promotes the health of both parent and child.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTKevin Shea, PharmDPharmacist Vytal Options PRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify current ACOG recommendations regarding cannabis use during pregnancy and lactation.2. Describe pharmacist strategies for screening, counseling, and reducing risks associated with cannabis use during the perinatal period.Rachel Maynard and Kevin Shea have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-25-377-H01-PInitial release date: 12/29/2025Expiration date: 12/29/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer’s disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer’s models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer’s care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTDawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFHProfessor of Pharmacy PracticeMidwestern UniversityPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current evidence on the use of microdose lithium in Alzheimer's disease.2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's.Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-25-375-H01-PInitial release date: 12/22/2025Expiration date: 12/22/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcastCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose.  0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram